Joan Connolly
Chief Tech/Sci/R&D Officer chez ALBIREO PHARMA, INC.
Profil
Joan Connolly is currently the Chief Technology Officer at Albireo Pharma, Inc. Her former position was Senior Vice President-Technical Operations at Stemline Therapeutics, Inc. She received an undergraduate degree from Queen's University.
Postes actifs de Joan Connolly
| Sociétés | Poste | Début |
|---|---|---|
| ALBIREO PHARMA, INC. | Chief Tech/Sci/R&D Officer | 13/04/2021 |
Anciens postes connus de Joan Connolly
| Sociétés | Poste | Fin |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Formation de Joan Connolly
| Queen's University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
